Arena Pharmaceuticals (ARNA) is soaring 14.55% after it presents data from Phase III trials of...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

Arena Pharmaceuticals (ARNA) is soaring 14.55% after it presents data from Phase III trials of its lorcaserin treatment which show that the drug "caused statistically significant weight loss compared to a placebo" among 7,500 obese and overweight adults after one year.